Genscript Biotech Corporation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Genscript Biotech Corporation
Just three years after its founding, Chinese cell therapy developer IASO Bio already has two assets in clinical development and the Nanjing firm has recently attracted $60m in financing. In an exclusive interview, its R&D head told Scrip that speed and partnerships are propelling Chinese developers on a trajectory to quickly catch up with the west in the emerging cell-therapy arena.
From cell therapy to digital health, from fast follower to innovator, China continues to gain traction with global health companies, underscored by its early emergence from the global pandemic and focus on certain technologies, with Boehringer Ingelheim the latest to be attracted.
A number of drug companies are set to learn the fate of their marketing authorization applications in the EU this week.
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
- Contract Research, Toxicology Testing-CRO
- Research, Analytical Equipment & Supplies
Drug Discovery Tools
- Large Molecule
- Other Names / Subsidiaries
- Legend Biotech USA Inc.
- Legend Biotech Ireland Limited
- Nanjing GenScript Co Ltd
- Nanjing Legend Biotechnology Co., Ltd.